Panacea's pentavalent vaccine set to regain WHO prequalification
This article was originally published in Scrip
Executive Summary
Panacea Biotec, India's second largest vaccine producer, has indicated that its pentavalent vaccine is set to be "re-prequalified" by the World Health Organization (WHO), around two years after the product was delisted after quality systems at the firm's production site failed to meet requisite standards.